What investment strategy does TechLife Capital focus on?

TechLife Capital focuses on Growth strategies in the private equity space.

How many portfolio companies does TechLife Capital have?

TechLife Capital has 14 active portfolio companies and 2 completed exits and 2 funds tracked on GP Intel.

Where is TechLife Capital headquartered?

TechLife Capital is headquartered in Paris, France.

What is TechLife Capital's assets under management?

TechLife Capital manages approximately €150M in assets under management.

When was TechLife Capital founded?

TechLife Capital was founded in 2018.

What sectors does TechLife Capital invest in?

TechLife Capital invests across Healthcare, Software, Business Services.

Home/GPs/TechLife Capital

TechLife Capital

Paris, France·Founded 2018·

Growth Equity

·techlifecapital.com

Paris-based growth equity firm founded in 2018, focused on mid-market healthcare and technology scale-ups through TechLife Capital I (2018, EUR 100M flagship) and TechLife Capital II (2024). AMF-registered and TIBI-labelled for innovation financing, with 3 partners and 10 operating partners split between healthcare and technology. First exits in 2025: Atempo, sold to the HorizonH consortium in May, and Maxxing, merged with Optimix Solutions in July at an IRR above 50 percent.

AUM

€150M

Funds

vintages 2018–2024

Portfolio

Exits

SectorsHealthcare Software Business Services

Key facts

HQParis, France

Founded2018

Websitetechlifecapital.com

Recent exits

Atempo

TMT2025 · 7yr hold

Maxxing

TMT2025 · 5yr hold

Coverage notes

2 funds tracked, 16 portfolio companies (14 active · 2 realized). Verified weekly from public filings and deal announcements.

Sector breakdown

16 companies

TMT

8 · 50%

HealthTech

2 · 13%

Biotech

2 · 13%

MedTech

1 · 6%

Software

1 · 6%

Pharma

1 · 6%

Healthcare

1 · 6%

Funds & portfolio

Every fund TechLife Capital has raised, with its portfolio companies. Hand-checked from public filings.

2 funds

TechLife Capital IIGrowth

2024 · 2yr€50M7 active

Unrealized

7 held

Company	Sector	Geo	Entry
Ad Scientiam	HealthTech	France	2025
Créative	TMT	France	2025
Evolutis	MedTech	France	2023
Flash Therapeutics	Biotech	France	2021
MyData Trust	TMT	France	2021
Quinten Health	HealthTech	France	2022
Studia	Software	France	2026

Ad ScientiamActive

HealthTech

France· Entry 2025

CréativeActive

TMT

France· Entry 2025

EvolutisActive

MedTech

France· Entry 2023

Flash TherapeuticsActive

Biotech

France· Entry 2021

MyData TrustActive

TMT

France· Entry 2021

Quinten HealthActive

HealthTech

France· Entry 2022

StudiaActive

Software

France· Entry 2026

TechLife Capital IGrowth

2018 · 8yr€100M7 active · 2 realized

Unrealized

7 held

Company	Sector	Geo	Entry
ADS	TMT	France	2019
CNSI	TMT	France	2020
MDT	TMT	France	2020
MITEM Pharma	Pharma	France	2020
RNAlead	Biotech	France	2021
Venn	TMT	France	2020
XPath	Healthcare	France	2021

ADSActive

TMT

France· Entry 2019

CNSIActive

TMT

France· Entry 2020

MDTActive

TMT

France· Entry 2020

MITEM PharmaActive

Pharma

France· Entry 2020

RNAleadActive

Biotech

France· Entry 2021

VennActive

TMT

France· Entry 2020

XPathActive

Healthcare

France· Entry 2021

Realized

2 exits

Company	Sector	Geo	Entry	Exit	Type	Buyer	MOIC
Atempo	TMT	France	2018	2025	Trade Sale		–
Maxxing	TMT	France	2020	2025	Trade Sale		–

AtempoExited 2025

TMT

France· Entry 2018

Trade Saleto

MaxxingExited 2025

TMT

France· Entry 2020

Trade Saleto

Track TechLife Capital

Saved GPs appear in your watchlist, one click from your workspace.

About TechLife Capital

TechLife Capital is a Paris-based growth equity private equity firm with €150 million of assets under management, founded in 2018 and focused on Healthcare and Technology mid-market scale-ups. The firm deploys across TechLife Capital I (vintage 2018, €100M flagship) and TechLife Capital II (vintage 2024, €50M proxy), with AMF registration and Tibi label alignment supporting institutional French limited partner relationships.

Investment thesis

TechLife Capital targets European Healthcare and Technology mid-market scale-ups, deploying growth equity capital with equity tickets typically ranging from €5 million to €20 million per transaction. Sector focus spans HealthTech, MedTech, enterprise software and selective B2B technology verticals, with the dual healthcare-technology mandate enabling cross-vertical insights into digital health and HealthTech innovation themes.

Recent activity

Recent realised exits include Atempo (TMT, 2025) and Maxxing (TMT, 2025), reflecting active distribution across the technology portfolio. The platform tracks 2 funds, 11 active portfolio companies and 2 realised exits across the multi-vintage healthcare and technology growth equity programme. Detailed buyer names and multiple data available on Pro at €29/month.